Robert Stagg, SVP, Clinical R&D at OncoMed Pharmaceuticals Inc (OMED), sold 927 shares at $2.01 ($2K) on 2018-10-10, disclosed to the SEC on 2018-10-11.
Open-market sale of $2k OMED by SVP, Clinical R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |